We recently compiled a list of the 10 Best Penny Stocks to Buy for 2025. In this article, we are going to take a look at ...

Zilurgisertib fumarate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome.

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Anthony Olson was told he’d die without treatment and to ignore a negative biopsy. He’s one of many patients who may have ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic ...

Myelodysplastic syndrome (MDS) refers to a group of bone marrow disorders characterised by ineffective hematopoiesis. It often involves an expansion of progenitor cells that fail to mature into ...